Abstract
➢ Giant cell tumor of bone (GCTB) is a benign, locally aggressive, osteolytic lesion. Typical treatment involves extended intralesional curettage or en bloc resection.➢ Denosumab is a fully human monoclonal antibody with inhibitory effects on RANKL (receptor activator of nuclear factor-κB ligand) that has shown early promise as a possible treatment adjuvant for GCTB.➢ Current clinical trials of denosumab for GCTB have shown >85% clinical, radiographic, and histological responses.➢ Case reports have demonstrated complete response or tumor stabilization with denosumab, allowing for less invasive surgical procedures. Current indications for denosumab in GCTB include lesions in the spine, sacrum, pelvis, and challenging lesions in upper and lower-extremity locations.➢ Denosumab may be a therapeutic option in patients with unresectable or metastatic GCTB, but optimal length and dosing of treatment and long-term effects are unknown. Most concerning, potential rates of rapid recurrence post-treatment or pseudo-sarcomatous transformation following treatment cessation are still uncertain.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
